In their 7-year study extension¹ on the prevention of fractures with the human monoclonal antibody denosumab, Henry Bone and colleagues report low rates of adverse events and low fracture incidences compared with those observed during the original FREEDOM trial. The study has limitations that ought to be pointed out.

中文翻译：

---

地诺单抗治疗绝经后骨质疏松症妇女

在长达7年的关于使用人源单克隆抗体denosumab预防骨折的研究扩展^1中，Henry Bone及其同事报告说，与最初的FREEDOM试验相比，不良事件发生率低且骨折发生率低。该研究具有应指出的局限性。